Home
KALV
KALV News

Latest KalVista Pharmaceuticals Inc. (KALV) News on November 8, 2024

KalVista Secures $184M Financing for Sebetralstat Launch

TipRanks

3 days ago

KalVista Secures $184M Financing for Sebetralstat Launch

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

3 days ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

4 days ago

KalVista Closes Royalty Financing Deal with DRI Healthcare, Prices $55 Million Offering

MT Newswires

4 days ago

DRI Healthcare Trust Acquires Royalty Stake in Global Sales of Sebetralstat

KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million

Business Wire

4 days ago

KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million

KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust

Business Wire

4 days ago

KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust

KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology

Business Wire

11 days ago

KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology

KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)

Business Wire

21 days ago

KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)

KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum

Business Wire

a month ago

KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a month ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

High Growth Tech Stocks To Watch In The United States

Simply Wall St.

a month ago

High Growth Tech Stocks To Watch In The United States

MT Newswires

a month ago

KalVista Submits Marketing Applications for Angioedema Treatment Sebetralstat

KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema

Business Wire

a month ago

KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema

KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)

Business Wire

a month ago

KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)

MT Newswires

2 months ago

KalVista Pharmaceuticals Names Brian Piekos Finance Chief

KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

Business Wire

2 months ago

KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

KalVista Appoints Brian Piekos as Chief Financial Officer

Business Wire

2 months ago

KalVista Appoints Brian Piekos as Chief Financial Officer

KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024

Business Wire

2 months ago

KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024

KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update

Business Wire

2 months ago

KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

2 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

2 months ago

KalVista Says New Drug Application for Sebetralstat Accepted by FDA

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

Business Wire

2 months ago

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium

Business Wire

2 months ago

KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium

KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema

Business Wire

3 months ago

KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema

Here's Why We're Not Too Worried About KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

Simply Wall St.

3 months ago

Here's Why We're Not Too Worried About KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

3 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

Business Wire

4 months ago

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

4 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

4 months ago

KalVista Starts Hereditary Angioedema Trial in Pediatric Patients

KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11

Business Wire

4 months ago

KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11

MT Newswires

5 months ago

KalVista Pharmaceuticals Submits New Drug Application to FDA for Investigational Hereditary Angioedema Treatment

KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema

Business Wire

5 months ago

KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024

Business Wire

5 months ago

KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

5 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024

Business Wire

5 months ago

KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024

KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema

Business Wire

5 months ago

KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema

MT Newswires

5 months ago

KalVista Prospective Treatment for Swelling Disorder Meets Objectives -- Shares Rise

KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024

Business Wire

5 months ago

KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024

Breakeven On The Horizon For KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Simply Wall St.

6 months ago

Breakeven On The Horizon For KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

Business Wire

6 months ago

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

6 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year

Business Wire

6 months ago

KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year

KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors

Business Wire

7 months ago

KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors

ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors

Barrons.com

7 months ago

ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors

KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference

Business Wire

7 months ago

KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

7 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas

Business Wire

8 months ago

KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas

KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat

Business Wire

8 months ago

KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

Business Wire

8 months ago

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

Business Wire

8 months ago

KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer

Business Wire

8 months ago

KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer

KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference

Business Wire

8 months ago

KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

8 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Business Wire

8 months ago

KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Business Wire

8 months ago

KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat

Business Wire

9 months ago

KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Business Wire

9 months ago

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants

Business Wire

9 months ago

KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants

KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Business Wire

9 months ago

KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Reuters

9 months ago

UPDATE 1-KalVista meets main goals in late-stage trial for genetic disease

Reuters

9 months ago

KalVista meets main goals in late-stage trial for skin condition treatment

KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema

Business Wire

9 months ago

KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema

Kalvista pill succeeds in late-stage study for rare swelling disorder

BioPharma Dive

9 months ago

Kalvista pill succeeds in late-stage study for rare swelling disorder

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

9 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Strength Seen in Silence Therapeutics PLC Sponsored ADR (SLN): Can Its 15.4% Jump Turn into More Strength?

Zacks

9 months ago

Strength Seen in Silence Therapeutics PLC Sponsored ADR (SLN): Can Its 15.4% Jump Turn into More Strength?

Bank of America Is Upbeat, but Preparing for a Worst-Case Outcome

Motley Fool

9 months ago

Bank of America Is Upbeat, but Preparing for a Worst-Case Outcome

Is Now An Opportune Moment To Examine Hanesbrands Inc. (NYSE:HBI)?

Simply Wall St.

9 months ago

Is Now An Opportune Moment To Examine Hanesbrands Inc. (NYSE:HBI)?

First Community Bankshares Full Year 2023 Earnings: In Line With Expectations

Simply Wall St.

9 months ago

First Community Bankshares Full Year 2023 Earnings: In Line With Expectations

Uniti Group Inc. Announces Tax Reporting Information for 2023 Distributions

GlobeNewswire

9 months ago

Uniti Group Inc. Announces Tax Reporting Information for 2023 Distributions

Forward Air to Complete Omni Acquisition at Lower Price Tag

The Wall Street Journal

10 months ago

Forward Air to Complete Omni Acquisition at Lower Price Tag

BURFORD CAPITAL APPOINTS PAMELA CORRIE AS AN INDEPENDENT NON-EXECUTIVE DIRECTOR

PR Newswire

10 months ago

BURFORD CAPITAL APPOINTS PAMELA CORRIE AS AN INDEPENDENT NON-EXECUTIVE DIRECTOR

Insider Sell: Chief Scientific Officer Edward Feener Sells 22,679 Shares of KalVista ...

GuruFocus.com

10 months ago

Insider Sell: Chief Scientific Officer Edward Feener Sells 22,679 Shares of KalVista ...

Insider Sell: Chief Scientific Officer Edward Feener Sells 17,321 Shares of KalVista ...

GuruFocus.com

10 months ago

Insider Sell: Chief Scientific Officer Edward Feener Sells 17,321 Shares of KalVista ...

OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser’s Option to Purchase Additional Notes

GlobeNewswire

10 months ago

OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser’s Option to Purchase Additional Notes

Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference

Business Wire

10 months ago

Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference

BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited Revenue

PR Newswire

10 months ago

BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited Revenue

Insomnia Cookies Sweetens Customer Loyalty by Selecting PAR Technology’s Punchh® Innovative Platform

Business Wire

10 months ago

Insomnia Cookies Sweetens Customer Loyalty by Selecting PAR Technology’s Punchh® Innovative Platform

Insider Sell: CEO Thomas Crockett Sells 30,000 Shares of KalVista Pharmaceuticals Inc (KALV)

GuruFocus.com

10 months ago

Insider Sell: CEO Thomas Crockett Sells 30,000 Shares of KalVista Pharmaceuticals Inc (KALV)

16 Most Promising Long-Term Stocks According to Analysts

Insider Monkey

10 months ago

16 Most Promising Long-Term Stocks According to Analysts

Ericsson (ERIC) to Deploy Private 5G Networks Across Spain

Zacks

a year ago

Ericsson (ERIC) to Deploy Private 5G Networks Across Spain

KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in Pharmacology

Business Wire

a year ago

KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in Pharmacology

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical

Zacks

a year ago

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical

KalVista Pharmaceuticals Inc (KALV) Reports Second Fiscal Quarter Results

GuruFocus.com

a year ago

KalVista Pharmaceuticals Inc (KALV) Reports Second Fiscal Quarter Results

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

Business Wire

a year ago

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

Baytex Announces 2024 Budget and Five-Year Outlook with Continued Focus on Free Cash Flow Generation and Shareholder Returns

Newsfile

a year ago

Baytex Announces 2024 Budget and Five-Year Outlook with Continued Focus on Free Cash Flow Generation and Shareholder Returns

Argentina elected chainsaw-toting ‘king of the jungle’ Janvier Milei president — these are the companies to watch ahead of the coming economic ‘shock'

Moneywise

a year ago

Argentina elected chainsaw-toting ‘king of the jungle’ Janvier Milei president — these are the companies to watch ahead of the coming economic ‘shock'

Kingsoft Cloud Holdings Limited (NASDAQ:KC) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

Kingsoft Cloud Holdings Limited (NASDAQ:KC) Q3 2023 Earnings Call Transcript

Hayward Holdings' (NYSE:HAYW) Returns Have Hit A Wall

Simply Wall St.

a year ago

Hayward Holdings' (NYSE:HAYW) Returns Have Hit A Wall

Docebo Inc.'s (TSE:DCBO) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Simply Wall St.

a year ago

Docebo Inc.'s (TSE:DCBO) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Thomson Reuters StreetEvents

a year ago

Q3 2023 Revance Therapeutics Inc Earnings Call

Wheels Up Reports Third Quarter Results

PR Newswire

a year ago

Wheels Up Reports Third Quarter Results

Business Wire

a year ago

Legg Mason Partners Fund Advisor, LLC Announces Distributions for the Month of November 2023

Crescent Point Energy Corp. (TSE:CPG) Passed Our Checks, And It's About To Pay A CA$0.02 Dividend

Simply Wall St.

a year ago

Crescent Point Energy Corp. (TSE:CPG) Passed Our Checks, And It's About To Pay A CA$0.02 Dividend

Revance Therapeutics, Inc. (RVNC) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks

a year ago

Revance Therapeutics, Inc. (RVNC) Reports Q3 Earnings: What Key Metrics Have to Say

Associated Press Finance

a year ago

V2X: Q3 Earnings Snapshot

Share on Social Networks: